Efficacy and safety of transarterial chemoembolization with chemotherapy, PD-1/PD-L1 inhibitors, and tyrosine kinase inhibitors in unresectable intrahepatic cholangiocarcinoma

Table 1 Comparison of baseline characteristics between the two groups, n (%)

Baseline data	Experimental group (n = 41)	Control group (n = 42)	P value
Sex
Male	20 (48.8)	27 (64.3)	0.154
Female	21 (51.2)	15 (35.7)
Age
> 60	17 (41.5)	23 (54.8)	0.225
≤ 60	24 (58.5)	19 (45.2)
ECOG PS score
0	24 (58.5)	24 (57.1)	0.898
1	17 (41.5)	18 (42.9)
HBV infection
No	14 (34.1)	12 (28.6)	0.584
Yes	27 (65.9)	30 (71.4)
Cirrhosis
No	14 (34.1)	9 (21.4)	0.196
Yes	27 (65.9)	33 (78.6)
Child-Pugh
A	17 (41.5)	18 (42.9)	0.898
B	24 (58.5)	24 (57.1)
AFP (ng/mL)
< 400	34 (82.9)	30 (71.4)	0.213
≥ 400	7 (17.1)	12 (28.6)
CA19-9 (U/mL)
> 1000	7 (17.1)	10 (23.8)	0.447
≤ 1000	34 (82.9)	32 (76.2)
Max tumor size (mm)
> 50	20 (48.8)	24 (57.1)	0.445
≤ 50	21 (51.2)	18 (42.9)
Tumor number
One	7 (17.1)	6 (14.3)	0.727
More than one	34 (82.9)	36 (85.7)
Large vessel invasion
No	25 (61.0)	32 (76.2)	0.135
Yes	16 (39.0)	10 (23.8)
Extrahepatic metastasis
No	25 (61.0)	21 (50.0)	0.315
Yes	16 (39.0)	21 (50.0)
TKIs
Lenvatinib	26 (63.4)	24 (57.1)	0.121
Anlotinib	11 (26.8)	7 (16.7)
Sofantinib	4 (9.8)	11 (26.2)
PD1/PD-L1 inhibitors
Camrelizumab	19 (46.3)	21 (50.0)	0.815
Toripalimab	14 (34.2)	15 (35.7)
Pembrolizumab	8 (19.5)	6 (14.3)

ECOG PS: Eastern Cooperative Oncology Group performance status; HBV: Hepatitis B virus; AFP: Alpha fetoprotein; CA19-9: Carbohydrate antigen 19-9; TKIs: Tyrosine kinase inhibitors; PD-1: Programmed death 1; PD-L1: Programmed cell death ligand 1.